Table 2.

Personalized prescription schemes.

Velocity (mm/day)	GTV2 Radius (cm)	P-SF (%)	P-M1 (cm)	P-TD1 (Gy)	P-M2 (cm)	P-Boost Delivery	P-Dose Policy
0.029 (slow-move)	1.0	0.021	3.0	45.6	1.5	Sequential	P5
	2.0	0.048	3.5	43.7	1.5	Sequential	P5
0.079 (average-move)	1.0	0.001	6.0 (max)	37.0	1.5	Sequential	P5
	2.0	0.001	6.0 (max)	38.3	1.5	Sequential	P5
0.13 (fast-move)	1.0	0.001	6.0 (max)	37.0	1.5	Sequential	P5
	2.0	0.328	6.0 (max)	32.9	2.5	Concurrent	P5

Personalized (P-) treatment margins (M₁ for GTV₁ and M₂ for GTV₂), total dose in the initial phase (TD₁), and dose policy are shown for each tumor studied. The tumor cell-surviving fraction (SF) using the personalized prescription is shown as a percentage of SF obtained from the standard prescription (M₁ = M₂ = 2 cm, TD₁ = 46 Gy).